Skip to content
Bored Studies
RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

MBX Biosciences · NCT07142707

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
124
US sites recruiting
4
Study start
September 3, 2025
Record last updated
June 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.

Being studied: MBX 4291; Placebo

Conditions: Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age of >18 to ≤65 years at the time of signing the informed consent.
  • Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline.
  • Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.

Exclusion Criteria

  • History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
  • History of currently active pancreatitis, type I and type II diabetes.
  • Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.
  • A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Recruiting US locations

Study contacts (from the official record)

  • Elisa Fabbrini, MD, PhD · 844-877-4473 · MBX4291.Clinicaltrials@mbxbio.com
  • Stewart Hallett · 844-877-4473 · MBX4291.Clinicaltrials@mbxbio.com
All weight loss studies in Florida →
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics,… (NCT07142707) | Bored Studies